Ocay, Sengyl B.
HRN: 26-20-79 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/27/2024
CO-AMOXICLAV 625MG (TAB)
11/27/2024
12/04/2024
ORAL
625 Mg
Every 8 Hours
Fracture
Waiting Final Action
Indication: Empiric Type of Infection: Bone & JointSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes